Drug Profile
BAN 0805
Alternative Names: ABBV-0805; BAN-0805; PD-0805Latest Information Update: 30 Nov 2022
Price :
$50
*
At a glance
- Originator BioArctic
- Developer AbbVie
- Class Antiparkinsonians; Monoclonal antibodies
- Mechanism of Action Alpha-synuclein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Parkinson's disease